COPD Exacerbation Vaccine Study

• Research type

  Research Study

• Full title

  A Phase II, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational vaccine GSK2838504A, when administered intramuscularly according to a 0, 2 month schedule to COPD patients aged 40 to 80 years

• IRAS ID

  140583

• Contact name

  Tom Wilkinson

• Contact email

  t.wilkinson@soton.ac.uk

• Eudract number

  2013-003062-13

• ISRCTN Number

  n/a

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  13/SC/0616

• Date of REC Opinion

  17 Dec 2013

• REC opinion

  Favourable Opinion